E
Evecxia Therapeutics
Leveraging the full therapeutic potential of amplified serotonin synthesis to treat mental illness
About Evecxia Therapeutics
Evecxia Therapeutics is a pioneering company focused on the therapeutic potential of 5-hydroxytryptophan (5-HTP) for treating mental illness. The company aims to address the unmet needs of patients whose conditions are not adequately managed by current therapies. Operating in the mental health sector, Evecxia's primary clients are individuals suffering from disabling mental illnesses such as depression and anxiety. The business model revolves around the development and commercialization of 5-HTP-based treatments, which are designed to improve the emotional well-being and overall quality of life for these patients. Revenue is generated through the sale of these specialized therapeutic products, as well as potential partnerships and licensing agreements with larger pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Founded
- 2013
- Headquarters
- Raleigh, United States
- Sector
- Biotech & Life Sciences
Knowledge graph
More headlines
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later1 investor entered at this stage
Collage Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Evecxia Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Evecxia Therapeutics on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.